Skip to main content
SpringerLink
Log in

Role of Matrix Metalloproteinases in the Development and Progression of Atherosclerosis

  • Chapter
  • First Online:
Proteases in Human Diseases

Abstract

Atherosclerosis underlies the majority of cardiovascular diseases and is accepted as a primary cause of mortality worldwide. Matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs) perform complex roles during the progression and development of atherosclerosis and subsequent plaque instability. Proposed actions of MMPs include extracellular matrix remodeling alongside regulation of vascular cell proliferation, migration and apoptosis including cell types such as monocytes, macrophages and vascular smooth muscle cells. As such, a large body of evidence from both in vitro and in vivo studies has shown that individual MMPs and TIMPs are utilized by distinct cell types to regulate their behavior. Consequently, it is now accepted that some MMPs promote the growth and development of advanced atherosclerotic plaques in experimental models whilst others do not . Similarly, human genetic and pathological findings reveal some MMPs correlate with vulnerable atherosclerotic plaque phenotypes, whereas others associate with stable lesions. Furthermore, broad-spectrum MMP inhibition in both mouse and man has proved ineffective at protecting from atherosclerotic plaque progression and instability. Considering the divergent effects MMPs exert on atherosclerotic lesions, selectively targeting individual deleterious MMPs may serve as a more efficacious therapeutic strategy. For example, our recent data demonstrate that a selective MMP-12 inhibitor retards atherosclerotic plaque progression in the apolipoprotein E (Apoe) mouse atherosclerosis model, whilst also promoting plaque stabilization through reducing monocyte recruitment into plaques whilst augmenting fibrosis. Similar studies have been conducted assessing MMP-13 inhibition. Accordingly, as our knowledge of the complex roles MMPs play during the development, progression and rupture of atherosclerotic plaques expands, new impetus is required for clinical trials evaluating the therapeutic potential of selective MMP inhibition, especially in the context of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Virmani R, Burke AP, Farb A et al (2006) Pathology of the vulnerable plaque. J Am Coll Cardiol 47(8):C13–C18

    Article  CAS  PubMed  Google Scholar 

  2. Libby P (2012) Inflammation in Atherosclerosis. Arterioscler Thromb Vasc Biol 32(9):2045–2051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Davies MJ (1996) Stability and instability: two faces of coronary atherosclerosis—the Paul Dudley White lecture 1995. Circulation 94(8):2013–2020

    Article  CAS  PubMed  Google Scholar 

  4. Hansson GK (2005) Mechanisms of disease—inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 352(16):1685–1695

    Article  CAS  PubMed  Google Scholar 

  5. Newby AC (2007) Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 17(8):253–258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dollery CM, Libby P (2006) Atherosclerosis and proteinase activation. Cardiovasc Res 69(3):625–635

    Article  CAS  PubMed  Google Scholar 

  7. Galis ZS, Sukhova GK, Lark MW et al (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li Z, Li L, Zielke HR et al (1996) Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 148:121–128

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Henney AM, Wakeley PR, Davies MJ et al (1991) Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci 88:8154–8158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Halpert I, Sires UI, Roby JD et al (1996) Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 93(18):9748–9753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Herman MP, Sukhova GK, Libby P et al (2001) Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 104:1899–1904

    Article  CAS  PubMed  Google Scholar 

  12. Schönbeck U, Mach F, Sukhova GK et al (1999) Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 189:843–853

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sukhova GK, Schonbeck U, Rabkin E et al (1999) Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99:2503–2509

    Article  CAS  PubMed  Google Scholar 

  14. Rajavashisth TB, Xu X-P, Jovinge S et al (1999) Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Circ Res 99:3101–3109

    Google Scholar 

  15. Uzui H, Harpf A, Liu M et al (2002) Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque. Role of activated macrophages and inflammatory cytokines. Circ Res 106:3024–3030

    Article  CAS  Google Scholar 

  16. Johnson JL (2007) Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 5(2):265–282

    Article  CAS  PubMed  Google Scholar 

  17. Newby AC, Johnson JL (2005) Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circ Res 97(10):958–960

    Article  CAS  PubMed  Google Scholar 

  18. Murphy G (2010) Fell-Muir lecture: metalloproteinases: from demolition squad to master regulators. Int J Exp Path 91(4):303–313

    Article  CAS  Google Scholar 

  19. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3):562–573

    Article  CAS  PubMed  Google Scholar 

  20. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circ Res 93:827–839

    Article  CAS  Google Scholar 

  21. Itoh Y, Seiki M (2006) MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 206(1):1–8

    Article  CAS  PubMed  Google Scholar 

  22. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719–3727

    Article  CAS  PubMed  Google Scholar 

  23. Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. BBA-Mol Cell Res 1803(1):55–71

    CAS  Google Scholar 

  24. Golledge J, Norman PE (2010) Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Arterioscler Thromb Vasc Biol 30(6):1075–1077

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Virmani R, Kolodgie FD, Burke AP et al (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20(5):1262–1275

    Article  CAS  PubMed  Google Scholar 

  26. Reel B, Sala-Newby GB, Huang WC et al (2011) Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes. Br J Pharmacol 163(8):1679–1690

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Matias-Roman S, Galvez BG, Genis L et al (2005) Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 105(10):3956–3964

    Article  CAS  PubMed  Google Scholar 

  28. May AE, Schmidt R, Bulbul O et al (2005) Plasminogen and matrix metalloproteinase activation by enzymatically modified low density lipoproteins in monocytes and smooth muscle cells. Thromb Haemostasis 93(4):710–715

    CAS  Google Scholar 

  29. Sithu SD, English WR, Olson P et al (2007) Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem 282(34):25010–25019

    Article  CAS  PubMed  Google Scholar 

  30. Di Gregoli K, George SJ, Jackson CL et al (2016) Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion. Cardiovasc Res 109(2):318–330

    Article  PubMed  CAS  Google Scholar 

  31. Di Gregoli K, Johnson JL (2012) Role of colony-stimulating factors in atherosclerosis. Curr Opin Lipidol 23(5):412–421

    Article  PubMed  CAS  Google Scholar 

  32. Libby P, Ridker PM, Hansson GK (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54(23):2129–2138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Schonbeck U, Libby P (2001) CD40 signaling and plaque instability. Circ Res 89:1092–1103

    Article  CAS  PubMed  Google Scholar 

  34. Newby AC (2012) Matrix metalloproteinase inhibition therapy for vascular diseases. Vasc Pharmacol 56(5–6):232–244

    Article  CAS  Google Scholar 

  35. Galis ZS, Sukhova GK, Libby P (1995) Microscopic localisation of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. Faseb J 9:974–980

    CAS  PubMed  Google Scholar 

  36. Johnson JL, Jackson CL, Angelini GD et al (1998) Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 18:1707–1715

    Article  CAS  PubMed  Google Scholar 

  37. Monaco C, Gregan SM, Navin TJ et al (2009) Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 120(24):2462–2469

    Article  CAS  PubMed  Google Scholar 

  38. Johnson JL, Jenkins NP, Huang W-C et al (2014) Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability. Mediat Inflamm 2014(ID276457):17

    Google Scholar 

  39. Thomas AC, Sala-Newby GB, Ismail Y et al (2007) Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-1 as a differential regulator of nitric oxide production. Arterioscler Thromb Vasc Biol 27:571–577

    Article  CAS  PubMed  Google Scholar 

  40. Johnson JL, Sala-Newby GB, Ismail Y et al (2008) Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol 28(9):1647–1653

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143

    Article  CAS  PubMed  Google Scholar 

  42. Pauly RR, Passaniti A, Bilato C et al (1994) Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 75:41–54

    Article  CAS  PubMed  Google Scholar 

  43. Haque NS, Fallon JT, Pan JJ et al (2004) Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood 103(4):1296–1304

    Article  CAS  PubMed  Google Scholar 

  44. Mason DP, Kenagy RD, Hasenstab D et al (1999) Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle migration and alters remodeling in the injured rat carotid artery. Circ Res 85:1179–1185

    Article  CAS  PubMed  Google Scholar 

  45. Filippov S, Koenig GC, Chun T-H et al (2005) MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med 5:663–671

    Article  CAS  Google Scholar 

  46. Johnson JL, Dwivedi A, Somerville M et al (2011) Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol 31(9):e35–e44

    Article  CAS  PubMed  Google Scholar 

  47. Yang SW, Lim L, Ju S et al (2015) Effects of matrix metalloproteinase 13 on vascular smooth muscle cells migration via Akt–ERK dependent pathway. Tissue Cell 47(1):115–121

    Article  CAS  PubMed  Google Scholar 

  48. Kajita M, Itoh Y, Chiba T et al (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153(5):893–904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Yu WH, Woessner JF, McNeish JD et al (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Gene Dev 16(3):307–323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Johnson C, Galis ZS (2004) Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 24(1):54–60

    Article  CAS  PubMed  Google Scholar 

  51. George SJ, Beeching CA (2006) Cadherin: catenin complex: a novel regulator of vascular smooth muscle cell behaviour. Atherosclerosis 188(1):1–11

    Article  CAS  PubMed  Google Scholar 

  52. Dwivedi A, Slater SC, George SJ (2009) MMP-9 and -12 cause N-cadherin shedding and thereby {beta}-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res 81(1):178–186

    Article  CAS  PubMed  Google Scholar 

  53. Haider N, Hartung D, Fujimoto S et al (2009) Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol 16(5):753–762

    Article  PubMed  PubMed Central  Google Scholar 

  54. Johnson JL, Devel L, Czarny B et al (2011) A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 31(3):528–535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Johnson JL, Baker AH, Oka K et al (2006) Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 113(20):2435–2444

    Article  CAS  PubMed  Google Scholar 

  56. Davies MJ (2000) The pathophysiology of acute coronary syndromes. Heart 83(3):361–366

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Davies MJ (2001) Going from immutable to mutable atherosclerotic plaques. Am J Cardiol 88(4A):2F–9F

    Article  CAS  PubMed  Google Scholar 

  58. Falk E, Nakano M, Bentzon JF et al (2013) Update on acute coronary syndromes: the pathologists’ view. Eur Heart J 34(10):719–728

    Article  CAS  PubMed  Google Scholar 

  59. Davì G, Patrono C (2007) Platelet activation and atherothrombosis. New Engl J Med 357(24):2482–2494

    Article  PubMed  Google Scholar 

  60. Amento EP, Ehsani N, Palmer H et al (1991) Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 11(5):1223–1230

    Article  CAS  Google Scholar 

  61. Powell WC, Fingleton B, Wilson CL et al (1999) The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9(24):1441–1447

    Article  CAS  PubMed  Google Scholar 

  62. Geng Y-J, Libby P (2002) Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol 22:1370–1380

    Article  CAS  PubMed  Google Scholar 

  63. de Boer OJ, van der Wal AC, Becker AE (2000) Atherosclerosis, inflammation, and infection. J Pathol 190:237–243

    Article  PubMed  Google Scholar 

  64. Newby AC (2005) Dual role of matrix metalloproteinases (matrixins) in neointima formation and atherosclerotic plaque rupture. Physiol Rev 85(1):1–31

    Article  CAS  PubMed  Google Scholar 

  65. Plump AS, Smith JD, Hayek T et al (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343–353

    Article  CAS  PubMed  Google Scholar 

  66. Nakashima Y, Plump AS, Raines EW et al (1994) ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol 14(1):133–140

    Article  CAS  Google Scholar 

  67. Ishibashi S, Brown MS, Goldstein JL et al (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92(2):883–893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Jackson CL, Bennett MR, Biessen EAB et al (2007) Assessment of unstable atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27:714–720

    Article  CAS  PubMed  Google Scholar 

  69. Van der Laan PA, Reardon CA, Getz GS (2004) Site specificity of atherosclerosis. Arterioscler Thromb Vasc Biol 24:12–22

    Article  CAS  Google Scholar 

  70. Lemaître V, O’Byrne TK, Borczuk AC et al (2001) ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 107(10):1227–1234

    Article  PubMed  PubMed Central  Google Scholar 

  71. Gough PJ, Gomez IG, Wille PT et al (2006) Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest 116(1):59–69

    Article  CAS  PubMed  Google Scholar 

  72. de Nooijer R, Verkleij CJ, von der Thuesen JH et al (2006) Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions, but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 26:340–346

    Article  PubMed  CAS  Google Scholar 

  73. Liang J, Liu E, Yu Y et al (2006) Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 113:1993–2001

    Article  CAS  PubMed  Google Scholar 

  74. Kuzuya M, Nakamura K, Sasaki T et al (2006) Effect of MMP-2 deficiency on atherosclerotic lesion formation in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 26(5):1120–1125

    Article  CAS  PubMed  Google Scholar 

  75. Kuzuya M, Kanda S, Sasaki T et al (2003) Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 108(11):1375–1381

    Article  CAS  PubMed  Google Scholar 

  76. Silence J, Lupu F, Collen D et al (2001) Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 21:1440–1445

    Article  CAS  PubMed  Google Scholar 

  77. Johnson JL, George SJ, Newby AC et al (2005) Divergent effects of matrix metalloproteinases -3, -7, -9 and -12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 102(43):15575–15580

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Luttun A, Lutgens E, Manderveld A et al (2004) Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 109(11):1408–1414

    Article  CAS  PubMed  Google Scholar 

  79. Williams H, Johnson JL, Jackson CL et al (2010) MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc Res 87(1):137–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Laxton RC, Hu Y, Duchene J et al (2009) A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res 105(9):921–929

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Deguchi JO, Aikawa E, Libby P et al (2005) Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation 112(17):2708–2715

    Article  CAS  PubMed  Google Scholar 

  82. Schneider F, Sukhova GK, Aikawa M et al (2008) Matrix metalloproteinase-14 deficiency in bone marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation 117(7):931–939

    Article  CAS  PubMed  Google Scholar 

  83. Silence J, Collen D, Lijnen HR (2002) Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 90:897–903

    Article  CAS  PubMed  Google Scholar 

  84. Di Gregoli K, Jenkins N, Salter R et al (2014) MicroRNA-24 regulates macrophage behavior and retards atherosclerosis. Arterioscler Thromb Vasc Biol 34(9):1990–2000

    Article  PubMed  CAS  Google Scholar 

  85. Stöhr R, Cavalera M, Menini S et al (2014) Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice. Atherosclerosis 235(2):438–443

    Article  PubMed  CAS  Google Scholar 

  86. Rouis M, Adamy C, Duverger N et al (1999) Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 100:533–540

    Article  CAS  PubMed  Google Scholar 

  87. Prescott MF, Sawyer WK, Von Linden-Reed J et al (1999) Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann NY Acad Sci 878:179–190

    Article  CAS  PubMed  Google Scholar 

  88. Johnson JL, Fritsche-Danielson R, Behrendt M et al (2006) Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc Res 71(3):586–595

    Article  CAS  PubMed  Google Scholar 

  89. Manning MW, Cassis LA, Daugherty A (2003) Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 23:483–488

    Article  CAS  PubMed  Google Scholar 

  90. Brown DL, Desai KK, Vakili BA et al (2004) Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 24:733–738

    Article  CAS  PubMed  Google Scholar 

  91. Axisa B, Loftus IM, Naylor AR et al (2002) Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33:2858–2864

    Article  CAS  PubMed  Google Scholar 

  92. Quillard T, Tesmenitsky Y, Croce K et al (2011) Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol 31(11):2464–2472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Ha M, Kim VN (2014) Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 15(8):509–524

    Article  CAS  PubMed  Google Scholar 

  94. Kim K-H, Jung J-Y, Son ED et al (2015) miR-526b targets 3[prime] UTR of MMP1 mRNA. Exp Mol Med 47:e178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Lee J, Lim S, Song B-W et al (2015) MicroRNA-29b inhibits migration and proliferation of vascular smooth muscle cells in neointimal formation. J Cell Biochem 116(4):598–608

    Article  CAS  PubMed  Google Scholar 

  96. Jing W, Jiang W (2015) MicroRNA-93 regulates collagen loss by targeting MMP3 in human nucleus pulposus cells. Cell Prolif 48(3):284–292

    Article  CAS  PubMed  Google Scholar 

  97. Jin H, Wang W (2015) MicroRNA-539 suppresses osteosarcoma cell invasion and migration in vitro and targeting matrix metallopeptidase-8. Int J Clin Exp Pathol 8(7):8075–8082

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Yu Y, Wang L, Liu T et al (2015) MicroRNA-204 suppresses trophoblast-like cell invasion by targeting matrix metalloproteinase-9. Biochem Biophys Res Commun 463(3):285–291

    Article  CAS  PubMed  Google Scholar 

  99. Wang Y-Y, Li H, Wang X-H et al (2016) Probucol inhibits MMP-9 expression through regulating miR-497 in HUVECs and apoE knockout mice. Thromb Res 140:51–58

    Article  CAS  PubMed  Google Scholar 

  100. Meng F, Zhang Z, Chen W et al (2016) MicroRNA-320 regulates matrix metalloproteinase-13 expression in chondrogenesis and interleukin-1β-induced chondrocyte responses. OARS 24(5):932–941

    CAS  Google Scholar 

  101. Li Y, Kuscu C, Banach A et al (2015) miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. Cancer Res 75(13):2674–2685

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Zhang H, Qi M, Li S et al (2012) microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 11(7):1454–1466

    Article  PubMed  CAS  Google Scholar 

  103. Son DJ, Kumar S, Takabe W et al (2013) The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 4

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cardiovascular Pathology, Faculty of Health Sciences, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Marlborough Street, Bristol, BS2 8HW, England, UK

    Karina Di Gregoli & Jason Lee Johnson

Authors
  1. Karina Di Gregoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason Lee Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason Lee Johnson .

Editor information

Editors and Affiliations

  1. Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, West Bengal, India

    Sajal Chakraborti

  2. Department of Biochemistry and Biophysics, University of Kalyani, Kalyani, West Bengal, India

    Tapati Chakraborti

  3. Department of Physiology, Faculty of Medicine, St. Boniface General Hospital, Institute of Cardiovascular Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

    Naranjan S. Dhalla

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Di Gregoli, K., Johnson, J.L. (2017). Role of Matrix Metalloproteinases in the Development and Progression of Atherosclerosis. In: Chakraborti, S., Chakraborti, T., Dhalla, N. (eds) Proteases in Human Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-10-3162-5_20

Download citation

Publish with us

Policies and ethics

Search

Navigation